Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines

Troy C. Sutton, Saborni Chakraborty, Vamsee V.A. Mallajosyula, Elaine W. Lamirande, Ketaki Ganti, Kevin W. Bock, Ian N. Moore, Raghavan Varadarajan, Kanta Subbarao

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The stem of the influenza A virus hemagglutinin (HA) is highly conserved and represents an attractive target for a universal influenza vaccine. The 18 HA subtypes of influenza A are phylogenetically divided into two groups, and while protection with group 1 HA stem vaccines has been demonstrated in animal models, studies on group 2 stem vaccines are limited. Thus, we engineered group 2 HA stem-immunogen (SI) vaccines targeting the epitope for the broadly neutralizing monoclonal antibody CR9114 and evaluated vaccine efficacy in mice and ferrets. Immunization induced antibodies that bound to recombinant HA protein and viral particles, and competed with CR9114 for binding to the HA stem. Mice vaccinated with H3 and H7-SI were protected from lethal homologous challenge with X-79 (H3N2) or A/Anhui/1/2013 (H7N9), and displayed moderate heterologous protection. In ferrets, H7-SI vaccination did not significantly reduce weight loss or nasal wash titers after robust 107 TCID50 H7N9 virus challenge. Epitope mapping revealed ferrets developed lower titers of antibodies that bound a narrow range of HA stem epitopes compared to mice, and this likely explains the lower efficacy in ferrets. Collectively, these findings indicate that while group 2 SI vaccines show promise, their immunogenicity and efficacy are reduced in larger outbred species, and will have to be enhanced for successful translation to a universal vaccine.

Original languageEnglish (US)
Article number36
Journalnpj Vaccines
Volume2
Issue number1
DOIs
StatePublished - Dec 1 2017

Fingerprint

Hemagglutinins
Human Influenza
Ferrets
Vaccines
Epitopes
H7N9 Subtype Influenza A Virus
Epitope Mapping
Antibodies
Influenza Vaccines
Influenza A virus
Neutralizing Antibodies
Nose
Recombinant Proteins
Virion
Weight Loss
Immunization
Vaccination
Animal Models
Monoclonal Antibodies

All Science Journal Classification (ASJC) codes

  • Immunology
  • Pharmacology
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Sutton, T. C., Chakraborty, S., Mallajosyula, V. V. A., Lamirande, E. W., Ganti, K., Bock, K. W., ... Subbarao, K. (2017). Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines. npj Vaccines, 2(1), [36]. https://doi.org/10.1038/s41541-017-0036-2
Sutton, Troy C. ; Chakraborty, Saborni ; Mallajosyula, Vamsee V.A. ; Lamirande, Elaine W. ; Ganti, Ketaki ; Bock, Kevin W. ; Moore, Ian N. ; Varadarajan, Raghavan ; Subbarao, Kanta. / Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines. In: npj Vaccines. 2017 ; Vol. 2, No. 1.
@article{6f92476b440246d9bba158b791982682,
title = "Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines",
abstract = "The stem of the influenza A virus hemagglutinin (HA) is highly conserved and represents an attractive target for a universal influenza vaccine. The 18 HA subtypes of influenza A are phylogenetically divided into two groups, and while protection with group 1 HA stem vaccines has been demonstrated in animal models, studies on group 2 stem vaccines are limited. Thus, we engineered group 2 HA stem-immunogen (SI) vaccines targeting the epitope for the broadly neutralizing monoclonal antibody CR9114 and evaluated vaccine efficacy in mice and ferrets. Immunization induced antibodies that bound to recombinant HA protein and viral particles, and competed with CR9114 for binding to the HA stem. Mice vaccinated with H3 and H7-SI were protected from lethal homologous challenge with X-79 (H3N2) or A/Anhui/1/2013 (H7N9), and displayed moderate heterologous protection. In ferrets, H7-SI vaccination did not significantly reduce weight loss or nasal wash titers after robust 107 TCID50 H7N9 virus challenge. Epitope mapping revealed ferrets developed lower titers of antibodies that bound a narrow range of HA stem epitopes compared to mice, and this likely explains the lower efficacy in ferrets. Collectively, these findings indicate that while group 2 SI vaccines show promise, their immunogenicity and efficacy are reduced in larger outbred species, and will have to be enhanced for successful translation to a universal vaccine.",
author = "Sutton, {Troy C.} and Saborni Chakraborty and Mallajosyula, {Vamsee V.A.} and Lamirande, {Elaine W.} and Ketaki Ganti and Bock, {Kevin W.} and Moore, {Ian N.} and Raghavan Varadarajan and Kanta Subbarao",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41541-017-0036-2",
language = "English (US)",
volume = "2",
journal = "npj Vaccines",
issn = "2059-0105",
publisher = "Nature Publishing Group",
number = "1",

}

Sutton, TC, Chakraborty, S, Mallajosyula, VVA, Lamirande, EW, Ganti, K, Bock, KW, Moore, IN, Varadarajan, R & Subbarao, K 2017, 'Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines', npj Vaccines, vol. 2, no. 1, 36. https://doi.org/10.1038/s41541-017-0036-2

Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines. / Sutton, Troy C.; Chakraborty, Saborni; Mallajosyula, Vamsee V.A.; Lamirande, Elaine W.; Ganti, Ketaki; Bock, Kevin W.; Moore, Ian N.; Varadarajan, Raghavan; Subbarao, Kanta.

In: npj Vaccines, Vol. 2, No. 1, 36, 01.12.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines

AU - Sutton, Troy C.

AU - Chakraborty, Saborni

AU - Mallajosyula, Vamsee V.A.

AU - Lamirande, Elaine W.

AU - Ganti, Ketaki

AU - Bock, Kevin W.

AU - Moore, Ian N.

AU - Varadarajan, Raghavan

AU - Subbarao, Kanta

PY - 2017/12/1

Y1 - 2017/12/1

N2 - The stem of the influenza A virus hemagglutinin (HA) is highly conserved and represents an attractive target for a universal influenza vaccine. The 18 HA subtypes of influenza A are phylogenetically divided into two groups, and while protection with group 1 HA stem vaccines has been demonstrated in animal models, studies on group 2 stem vaccines are limited. Thus, we engineered group 2 HA stem-immunogen (SI) vaccines targeting the epitope for the broadly neutralizing monoclonal antibody CR9114 and evaluated vaccine efficacy in mice and ferrets. Immunization induced antibodies that bound to recombinant HA protein and viral particles, and competed with CR9114 for binding to the HA stem. Mice vaccinated with H3 and H7-SI were protected from lethal homologous challenge with X-79 (H3N2) or A/Anhui/1/2013 (H7N9), and displayed moderate heterologous protection. In ferrets, H7-SI vaccination did not significantly reduce weight loss or nasal wash titers after robust 107 TCID50 H7N9 virus challenge. Epitope mapping revealed ferrets developed lower titers of antibodies that bound a narrow range of HA stem epitopes compared to mice, and this likely explains the lower efficacy in ferrets. Collectively, these findings indicate that while group 2 SI vaccines show promise, their immunogenicity and efficacy are reduced in larger outbred species, and will have to be enhanced for successful translation to a universal vaccine.

AB - The stem of the influenza A virus hemagglutinin (HA) is highly conserved and represents an attractive target for a universal influenza vaccine. The 18 HA subtypes of influenza A are phylogenetically divided into two groups, and while protection with group 1 HA stem vaccines has been demonstrated in animal models, studies on group 2 stem vaccines are limited. Thus, we engineered group 2 HA stem-immunogen (SI) vaccines targeting the epitope for the broadly neutralizing monoclonal antibody CR9114 and evaluated vaccine efficacy in mice and ferrets. Immunization induced antibodies that bound to recombinant HA protein and viral particles, and competed with CR9114 for binding to the HA stem. Mice vaccinated with H3 and H7-SI were protected from lethal homologous challenge with X-79 (H3N2) or A/Anhui/1/2013 (H7N9), and displayed moderate heterologous protection. In ferrets, H7-SI vaccination did not significantly reduce weight loss or nasal wash titers after robust 107 TCID50 H7N9 virus challenge. Epitope mapping revealed ferrets developed lower titers of antibodies that bound a narrow range of HA stem epitopes compared to mice, and this likely explains the lower efficacy in ferrets. Collectively, these findings indicate that while group 2 SI vaccines show promise, their immunogenicity and efficacy are reduced in larger outbred species, and will have to be enhanced for successful translation to a universal vaccine.

UR - http://www.scopus.com/inward/record.url?scp=85042233316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042233316&partnerID=8YFLogxK

U2 - 10.1038/s41541-017-0036-2

DO - 10.1038/s41541-017-0036-2

M3 - Article

C2 - 29263889

AN - SCOPUS:85042233316

VL - 2

JO - npj Vaccines

JF - npj Vaccines

SN - 2059-0105

IS - 1

M1 - 36

ER -